Company intelligence / Profile preview

Onconova Therapeutics, Inc.

Newtown, Pennsylvania, United Statesonconova.com ↗

Ownership: Public · ONTX
Development stage: Phase 2

Overview

Onconova Therapeutics merged with Trawsfynydd Therapeutics in April 2024 to form Traws Pharma, Inc. The company is developing narazaciclib (formerly ON 123300), a multi-kinase CDK4/6 inhibitor, currently in Phase 1/2a trials for endometrial cancer. The company also has investigator-sponsored studies for rigosertib in combination with nivolumab for KRAS+ non-small cell lung cancer and as monotherapy for advanced squamous cell carcinoma.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesMulti-kinase inhibitors
Industry: Biotech

Drug pipeline

3 assets

narazaciclib

Phase 1/2

Indications: Endometrial cancer, Metastatic breast cancer

2 more assets in the full pipeline.

Partnerships

HanX Biopharmaceuticals

Beyond the preview

Go deeper on Onconova Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onconova Therapeutics, Inc..